During these challenging times, the SIU Office of Research, uCARE, would like to help patients whose care has been disrupted by the COVID-19 pandemic. The SIU is pleased to share the news that the uCARE study, The feasibility and acceptability of a (mobile) application for men with LUTS/BPH: a pilot study (ClinicalTrials.gov ID: NCT03228485, uCARE 2018-002), is now open to both naïve and medically treated patients. This means the mobile app, MyBPH Care, associated with this study has been modified to allow the urologists and physicians in the five participating countries: Portugal, Italy, Spain, Greece and Turkey, manage their patients (both naïve and those under medical treatment) remotely via the MyBPH Care app. The amended protocol has now been approved in Italy and Greece.
This change in the inclusion criteria for the study was spearheaded by Dr. Mauro Gacci, urologist from Italy, and by Dr. Stavros. Gravas, urologist from Greece and lead investigator of the study.
We would like to thank GlaxoSmithKline and Dr. Nuno Azevedo, urologist and CEO of Ydeal, for their kind and generous support of this important initiative.
For more information about the study, The feasibility and acceptability of a (mobile) application for men with LUTS/BPH: a pilot study (ClinicalTrials.gov ID: NCT03228485, uCARE 2018-002) associated with the MyBPH Care mobile app, please click here.
SIU Statement on COVID-19 New on SIU Academy: Urology and COVID-19 Webinar and Resource Centre
